Haemophilia A patients

Release date: September 2020

You asked

I am looking for the following information for the period April 2020 to present:

  • The number of Haemophilia A patients on prophylaxis with Emicizumab, Long acting Factor VIII Product and Short acting Factor FVIII Product?
  • The number of Haemophilia A patients with on demand treatment using Emicizumab, Long acting Factor VIII Product and Short acting Factor FVIII Product?
  • The number of Haemophilia A patients with inhibitors currently undergoing ITI and what types of products are they on?
  • The number of Haemophilia B patients on prophylaxis with long acting Factor IX Product and short acting Factor IX Product?
  • The number of Haemophilia B patients with on demand treatment using Long acting Factor IX Product and Short acting Factor IX Product?
  • The number of von Willebrand disease patients on Prophylaxis (ideally with breakdown of type of vWD) and what types of products are they on?
  • The number of von Willebrand disease patients with on demand treatment (ideally with breakdown of type of vWD) and what types of products are they on?
  • The number of von Willebrand disease patients on intermittent Prophylaxis (ideally with breakdown of type of vWD) and what types of products are they on?

Our response

Manchester CCG does not hold this information. 

These are NHS England commissioned medicines/specialist conditions that are prescribed within acute trusts.